Butyphthalide in Combination With Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke
Status:
Completed
Trial end date:
2021-05-29
Target enrollment:
Participant gender:
Summary
Acute ischemic stroke (AIS) is the most common type of stroke, which has high rate of
morbidity, mortality and disability. A large number of studies have confirmed that the
thrombolytic therapy can effectively open blood vessels and improve the functional prognosis
of acute ischemic stroke. Therefore, all guidelines recommend giving thrombolysis treatment
to acute ischemic stroke patients within 4.5 hours of onset. However, about 1/3 patients
receiving thrombolysis will have good prognosis, while a large number of patients will still
be disabled and even dead. How to improve the neurofunctional prognosis of thrombolytic
patients has been a hot topic in the world.
Butyl phthalide is type I chemical drugs. Some multicenter randomized, double-blind,
placebo-controlled clinical trials have showed that acute ischemic stroke patients taking
butyl phthalide has better lateral branch circulation and living ability score than patients
taking placebo. Besides, butyl phthalide treatment is safe. The animal experiment indicated
that buphthalein could significantly improve secondary side branch circulation, recover the
microarterial diameter of the soft meninges in the ischemic region and increase the blood
flow rate.
Based on the discussion, we assume that: giving butyl phthalide to patients with acute
ischemic stroke in advance, might promote and improve the formation of collateral circulation
to freeze ischemia penumbra. Based on this hypothesis, we would like to explore the efficacy
and safety of butyl phthalide combined with rtPA thrombolysis in the treatment of acute
ischemic stroke.